Normalization of CSF pTau measurement by Aβ₄₀ improves its performance as a biomarker of Alzheimer's disease.

ABSTRACT:

Background

Alzheimer's disease (AD)-related tauopathy can be measured with CSF phosphorylated tau (pTau) and tau PET. We aim to investigate the associations between these measurements and their relative ability to predict subsequent disease progression.

Methods

In 219 cognitively unimpaired and 122 impaired Alzheimer's Disease Neuroimaging Initiative participants with concurrent amyloid-β (Aβ) PET (¹⁸F-florbetapir or ¹⁸F-florbetaben), ¹⁸F-flortaucipir (FTP) PET, CSF measurements, structural MRI, and cognition, we examined inter-relationships between these biomarkers and their predictions of subsequent FTP and cognition changes.

Results

The use of a CSF pTau/Aβ₄₀ ratio eliminated positive associations we observed between CSF

SUBMITTER: Guo T 

PROVIDER: S-EPMC7429887 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature